Which calcium channel blocker has the least risk of enhancing the effects of topical timolol and inducing bradycardia or heart failure?

Which calcium channel blocker has the least risk of enhancing the effects of topical timolol and inducing bradycardia or heart failure?

• A. Diltiazem
• B. Verapamil
• C. Nifedipine
• D. Amlodipine

Answer: (C)

The main idea here is how combining a calcium channel blocker with a beta-blocker can affect the heart’s rate and pumping. Timolol applied to the eye can still get into the bloodstream and act like a beta-blocker systemically. When you pair that with a calcium channel blocker, the risk of too much slowing of the heart rate or reducing heart function depends on the CCB’s effects on the heart’s conduction system. Non-dihydropyridine CCBs (like verapamil and diltiazem) strongly depress AV nodal conduction and can meaningfully slow the heart rate. When these are used with a beta-blocker, the risk of bradycardia, AV block, and even heart failure goes up. Dihydropyridine CCBs (like nifedipine and amlodipine) mainly cause vasodilation with little direct slowing of AV nodal conduction. They’re less likely to add to bradycardia or heart failure due to beta-blockade. Among the options, nifedipine is the dihydropyridine that's often cited as having the lowest risk of synergistically depressing cardiac conduction when used with a beta-blocker, making it the best choice in this context. So, the reasoning relies on the distinction between non-dihydropyridine CCBs (more AV nodal conduction suppression) and dihydropyridines (less conduction impact).

The main idea here is how combining a calcium channel blocker with a beta-blocker can affect the heart’s rate and pumping. Timolol applied to the eye can still get into the bloodstream and act like a beta-blocker systemically. When you pair that with a calcium channel blocker, the risk of too much slowing of the heart rate or reducing heart function depends on the CCB’s effects on the heart’s conduction system.

Non-dihydropyridine CCBs (like verapamil and diltiazem) strongly depress AV nodal conduction and can meaningfully slow the heart rate. When these are used with a beta-blocker, the risk of bradycardia, AV block, and even heart failure goes up.

Dihydropyridine CCBs (like nifedipine and amlodipine) mainly cause vasodilation with little direct slowing of AV nodal conduction. They’re less likely to add to bradycardia or heart failure due to beta-blockade. Among the options, nifedipine is the dihydropyridine that's often cited as having the lowest risk of synergistically depressing cardiac conduction when used with a beta-blocker, making it the best choice in this context.

So, the reasoning relies on the distinction between non-dihydropyridine CCBs (more AV nodal conduction suppression) and dihydropyridines (less conduction impact).